V
Vaxxas
Commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines
About Vaxxas
Vaxxas is a pioneering company in the biotechnology sector, focused on revolutionizing the way vaccines are delivered. The company has developed a novel, needle-free vaccination technology that significantly improves the efficacy and performance of both existing and next-generation vaccines. Vaxxas primarily serves healthcare providers, pharmaceutical companies, and global health organizations. Operating in the global healthcare market, Vaxxas employs a business model that includes partnerships, licensing agreements, and direct sales to generate revenue. By collaborating with renowned organizations, Vaxxas maximizes the impact of its technology on a global scale. The company's innovative approach aims to create a healthier world by making vaccinations more effective and accessible. Keywords: biotechnology, needle-free, vaccines, healthcare, efficacy, innovation, partnerships, licensing, global health, technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Brisbane, Australia
- Employees
- 132
- Open positions
- None listed
- Dealroom signal
- 64.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Vaxxas.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Aug 2025 | $26M | — | SPRIM Global Investments | ↗ |
| SERIES DOther financing | Aug 2025 | $32M | $127M | Brandon Capital Partners · One Ventures · LGT Crestone Wealth Management · SPRIM Global Investments | ↗ |
Growth signals
Latest recorded traffic for Vaxxas is 2.7K monthly website visits, down 37.2% over the last three months. Vaxxas's team grew 2.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Innovation Connections
Bill & Melinda Gates Foundation
US Biomedical Advanced Research and Development Authority
Coalition for Epidemic Preparedness
Wellcome Trust
Series A3 investors entered at this stage
- HVHealthCare Ventures
Brandon Capital Partners
One Ventures
Series B and later4 investors entered at this stage
UniQuest Extension Fund
Endpoints Capital
SPRIM Global Investments
LGT Crestone Wealth Management
Other known investors2 additional known investors
The University of Queensland
UniQuest
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vaxxas on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vaxxas’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.